Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pretomanid - Global Alliance for TB Drug Development/Novartis

Drug Profile

Pretomanid - Global Alliance for TB Drug Development/Novartis

Alternative Names: Pa; PA 824

Latest Information Update: 19 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Global Alliance for TB Drug Development
  • Class 2 ring heterocyclic compounds; Antituberculars; Nitroimidazoles; Oxazines; Phenyl ethers; Small molecules
  • Mechanism of Action Cell wall inhibitors; Nitric oxide stimulants; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Tuberculosis

Most Recent Events

  • 10 Sep 2019 Medecins Sans Frontieres plans the phase II/III PRACTECAL-PKPD trial for Tuberculosis (Combination therapy) in Belarus and South Africa (PO) in October 2019 (NCT04081077)
  • 14 Aug 2019 TB Alliance anticipates the launch of pretomanid for Tuberculosis (Combination therapy, Treatment-resistant) in USA in 2019 (PO)
  • 14 Aug 2019 Pretomanid receives Qualified Infectious Disease Product status for Tuberculosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top